NCT01271374 - Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2011

Conditions

Hypertension

Interventions

DRUG

amlodipine and olmesartan

Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily

DRUG

losartan and HCTZ

Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily

Trial Locations (1)

30084

Atlanta Clinical Research Center, Tucker